Literature DB >> 28496859

Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.

Omar F Hassan1, Jassim Al Suwaidi1, Amar M Salam1.   

Abstract

Although atrial fibrillation (AF) is the most common sustained arrhythmia seen during daily cardiovascular physician practice, its management remained a challenge for cardiology physician as there was no single anti-arrhythmic agents proved to be effective in converting atrial fibrillation and kept its effectiveness in maintaining sinus rhythm over long term. Moreover all the anti-arrhythmic agents that are used in treatment of AF were potentially pro-arrhythmic especially in patients with coronary artery disease and structurally abnormal heart. Some of these drugs also have serious non cardiac side effects that limit its long term use in the management of atrial fibrillation. Several new and investigational anti-arrhythmic agents are emerging but data supporting their effectiveness and safety are still limited. In this systematic review we examine the efficacy and safety of these medications supported by the major published randomized trials, meta-analyses and review articles and conclude with a summary of guidelines recommendations.

Entities:  

Keywords:  Atrial fibrillation; anti-arrhythmic agents; conversion; sinus rhythm; treatment

Year:  2013        PMID: 28496859      PMCID: PMC5153068          DOI: 10.4022/jafib.864

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  122 in total

1.  Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter.

Authors:  J E Lindeboom; J H Kingma; H J Crijns; P H Dunselman
Journal:  Am J Cardiol       Date:  2000-04-15       Impact factor: 2.778

Review 2.  Efficacy of ibutilide for termination of atrial fibrillation and flutter.

Authors:  K A Ellenbogen; H F Clemo; B S Stambler; M A Wood; J T VanderLugt
Journal:  Am J Cardiol       Date:  1996-10-17       Impact factor: 2.778

3.  Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.

Authors:  R H Falk; A Pollak; S N Singh; T Friedrich
Journal:  J Am Coll Cardiol       Date:  1997-02       Impact factor: 24.094

4.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction: safety aspects and effect on atrial fibrillation. The Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group.

Authors:  M Møller; C T Torp-Pedersen; L Køber
Journal:  Congest Heart Fail       Date:  2001 May-Jun

5.  Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study.

Authors:  P E Vardas; G E Kochiadakis; N E Igoumenidis; A M Tsatsakis; E N Simantirakis; G I Chlouverakis
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

6.  Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.

Authors:  Sanjeev Saksena; April Slee; Albert L Waldo; Nick Freemantle; Mathew Reynolds; Yves Rosenberg; Snehal Rathod; Shannon Grant; Elizabeth Thomas; D George Wyse
Journal:  J Am Coll Cardiol       Date:  2011-11-01       Impact factor: 24.094

7.  A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.

Authors:  A John Camm; Alessandro Capucci; Stefan H Hohnloser; Christian Torp-Pedersen; Isabelle C Van Gelder; Brian Mangal; Gregory Beatch
Journal:  J Am Coll Cardiol       Date:  2011-01-18       Impact factor: 24.094

Review 8.  Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.

Authors:  Krista M Dale; C Michael White
Journal:  Ann Pharmacother       Date:  2007-03-27       Impact factor: 3.154

9.  Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols.

Authors:  G Boriani; M Biffi; A Capucci; G Botto; T Broffoni; M Ongari; G Trisolino; I Rubino; M Sanguinetti; A Branzi; B Magnani
Journal:  Pacing Clin Electrophysiol       Date:  1998-11       Impact factor: 1.976

10.  Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure.

Authors:  J G Cleland; H J Dargie; I N Findlay; J T Wilson
Journal:  Br Heart J       Date:  1987-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.